Using reflexology to prevent neuropathy from oxaliplatin in colorectal cancer patients
Feasibility and Benefits of Reflexology in the Prevention of Neuropathy Induced by Oxaliplatin in Colorectal Cancer
This study is testing if reflexology can help colorectal cancer patients feel better and reduce nerve pain while they are receiving oxaliplatin chemotherapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Toulouse, CHU de Toulouse) |
| Trial ID | NCT06251297 on ClinicalTrials.gov |
What this trial studies
This pilot study aims to evaluate the feasibility of using reflexology as a complementary treatment for patients undergoing oxaliplatin chemotherapy for colorectal cancer. Participants will receive reflexology sessions with each cycle of chemotherapy, and their quality of life and neuropathy symptoms will be assessed throughout the treatment period. The study is designed to gather initial data on the effectiveness of reflexology in managing chemotherapy-induced side effects, particularly neuropathy.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old who are starting oxaliplatin chemotherapy for colorectal cancer and can provide informed consent.
Not a fit: Patients with pre-existing neuropathy or contraindications to reflexology will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could help reduce the incidence of neuropathy in colorectal cancer patients receiving oxaliplatin, improving their quality of life.
How similar studies have performed: While reflexology has been explored in various supportive care contexts, this specific application in oxaliplatin-induced neuropathy is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age\>18 years treated for colorectal cancer in Digestive Oncology service Rangueil hospital * Initiation of intravenous oxaliplatin chemotherapy at 85 mg/m² on a bimonthly schedule. * Ability to understand and answer a self-questionnaire. * Life expectancy egal or over 12 weeks * Signed informed consent form Exclusion Criteria: * Pre-existing motor and/or sensitive neuropathy. * Reflexology treatment within the last 6 months. * Contraindication to reflexology: venous thrombosis, trauma, wound or metastasis of the foot. * Patient covered by a legal protection scheme.
Where this trial is running
Toulouse, CHU de Toulouse
- CHU de Toulouse — Toulouse, CHU de Toulouse, France (Recruiting)
Study contacts
- Principal investigator: Nadim FARES, MD — University Hospital, Toulouse
- Study coordinator: Nadim FARES, MD
- Email: fares.n@chu-toulouse.fr
- Phone: 05 61 32 21 42
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.